美国市场贡献40%海外收入,这家药企自建美国创新药商业化团队

医药魔方Invest
27 Mar

3月25日,复星医药发布2024年度业绩报告。财报显示,2024年,复星医药实现营业收入410.67亿元,归母净利润27.70亿元,同比增加16.08%;实现经营现金流44.77亿元,同比增长31.13%,高于当期经营性利润的增速, 同时通过资产结构优化和严格控制资本性支出等多项措施,实现自由现金流的提升。进一步聚焦创新药和高值器械业务发展,推进产品结构和策略转型,是此番复星医药实现如此亮眼成绩的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10